ReviewNPJ cardiovascular health2024
Strategies for chronic coronary disease: A brief guide for clinicians.
Review in NPJ cardiovascular health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2023 Multisociety Guidelines for the Management of Patients with Chronic Coronary Disease (CCD) is a collaborative effort between the American Heart Association (AHA) and the American College of Cardiology (ACC) that provides recommendations on the management of this condition. Efficient management of CCD involves non-pharmaceutical interventions that promote healthier lifestyles, such as increasing physical activity, adopting a balanced diet, and addressing tobacco misuse. These changes are critical to improving cardiovascular outcomes for individuals with CCD. In addition to lifestyle modifications, pharmacological and revascularization treatments also play an essential role in managing CCD. These treatments target the complex mechanisms of the disease, optimize cardiac function, and decrease the risk of adverse events. The combination of lifestyle changes and medicine-based medications enhances the quality of life and lowers mortality rates among individuals with CCD. This article review emphasizes the importance of non-pharmacological and pharmacological strategies that align with the AHA/ACC guidelines. In addition, the primary objective of this study is to enhance comprehension of the approaches that have led to better cardiovascular results for patients diagnosed with CCD.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.